Skip to main content

Topic

Biosimilars

854 published works

  1. Big Molecule Watch

    Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars

    By Yoko Bian

    On August 21, 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical (“Lotus”) for AVT34, a proposed biosimilar to IMFINZI® (durvalumab), and AVT87, a proposed biosimilar to HEMLIBRA®…

  2. Big Molecule Watch

    Biocon Announces Supplemental U.S. FDA Approval for Prefilled Autoinjector for YESINTEK

    By Allegra Padula

    On August 18, 2026, Biocon Ltd. (“Biocon”) announced that its U.S. subsidiary has received supplemental U.S. FDA approval for YESINTEK® (ustekinumab-kfce) in a single-dose prefilled autoinjector, 45 mg/0.5 mL and…

  3. Big Molecule Watch

    Takeda Files BPCIA Suit Against Polpharma Biologics For Vedolizumab Biosimilar

    By Michael Shriner

    On August 26, 2026, Takeda Pharmaceuticals USA, Inc. and Takeda Pharmaceuticals International AG (collectively, “Takeda”) filed a BPCIA complaint in the U.S. District Court for the District of New Jersey…

  4. Big Molecule Watch

    Biocon Launches Aflibercept Biosimilar in the United States

    By Timothy Beavers

    On August 3, 2026, Biocon Limited announced the commercial launch of its biosimilar YESAFILI (aflibercept-jbvf) in the United States.  YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor that is…

  5. Big Molecule Watch

    Amneal Completes Acquisition of Kashiv

    By Jeremy Jones

    On August 10, 2026, Amneal Pharmaceuticals, Inc. completed its acquisition of Kashiv BioSciences, LLC. According to Amneal, the acquisition results in “a fully integrated global biosimilars leader with end-to-end capabilities…

  6. Big Molecule Watch

    Fresenius Kabi and Dr. Reddy’s Announce FDA Approval of Rituximab Biosimilar

    By Sam Herron

    On August 1, 2026, Fresenius Kabi and Dr. Reddy’s Laboratories announced that the FDA had approved Dr. Reddy’s rituximab biosimilar, a biosimilar to Genentech’s RITUXAN® (rituximab).  Rituximab is a monoclonal…

  7. Big Molecule Watch

    Genentech Files BPCIA Patent Infringement Suit Against Biocon Over Proposed PERJETA Biosimilar

    By Sarah Adam

    On July 29, 2026, Genentech, Inc. (“Genentech”) and Hoffmann-La Roche Inc. filed a complaint in the U.S. District Court for the District of New Jersey against Biocon Biologics Inc. (“Biocon”)…

  8. Big Molecule Watch

    FDA Approves Meitheal Pharmaceuticals’ Insulin Aspart Biosimilar GARZULYS

    By Darlene Staines

    On July 30, 2026, Meitheal Pharmaceuticals, Inc. (“Meitheal”) announced that the U.S. Food and Drug Administration (“FDA”) has approved GARZULYS (insulin apsart-fsan) injection.  GARZULYS, a biosimilar to Novo Nordisk’s NOVOLOG®…

  9. Big Molecule Watch

    Celltrion Targets European Secukinumab Market with EMA Filing for CT-P55

    By Wendy Leben

    Celltrion has submitted a Marketing Authorization Application to the European Medicines Agency (“EMA”) for CT-P55, its biosimilar to Novartis’ COSENTYX® (secukinumab). The application covers all indications held by COSENTYX® in…

  10. Big Molecule Watch

    Accord BioPharma Launches OSVYRTI® and JUBEREQ® Denosumab Biosimilars

    By Tara Thigpen

    On July 23, 2026, Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., announced the commercial launch of OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu), FDA-approved interchangeable biosimilars to Amgen’s PROLIA®…